Autolus Therapeutics PLC(AUTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUTL Autolus Therapeutics PLC

Market Closed 12-12 16:00:00 EST

1.61

+0.02

+1.26%

盘后1.63

+0.02+1.14%

19:48 EST

High1.69	Low1.59	Vol3.45M
Open1.61	D1 Closing1.59	Amplitude6.29%
Mkt Cap428.49M	Tradable Cap190.81M	Total Shares266.14M
T/O5.62M	T/O Rate2.91%	Tradable Shares118.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AUTL","market":"US","secType":"STK","nameCN":"Autolus Therapeutics PLC","latestPrice":1.61,"timestamp":1765573200000,"preClose":1.59,"halted":0,"volume":3448491,"hourTrading":{"tag":"盘后","latestPrice":1.6283,"preClose":1.61,"latestTime":"19:48 EST","volume":16000,"amount":25821.5158,"timestamp":1765586914413},"delay":0,"floatShares":118517614,"shares":266143286,"eps":-0.844634,"marketStatus":"Market Closed","change":0.02,"latestTime":"12-12 16:00:00 EST","open":1.61,"high":1.685,"low":1.585,"amount":5620608.5789268,"amplitude":0.062893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.844634,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1529640000000,"exchange":"NASDAQ","adjPreClose":1.59,"preHourTrading":{"tag":"盘前","latestPrice":1.61,"preClose":1.59,"latestTime":"09:27 EST","volume":26113,"amount":41800.8077806,"timestamp":1765549670029},"postHourTrading":{"tag":"盘后","latestPrice":1.6283,"preClose":1.61,"latestTime":"19:48 EST","volume":16000,"amount":25821.5158,"timestamp":1765586914413},"volumeRatio":1.3724109380250038,"impliedVol":1.1375,"impliedVolPercentile":0.516},"requestUrl":"/m/hq/s/AUTL","defaultTab":"news","newsList":[{"id":"2591830688","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2591830688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591830688?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:17","pubTimestamp":1765556266,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower late Friday morning, falling 1% to 1,646.41 on the S&P Europe Select ADR Index, which is up 1.3% so far this week","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4020","LYG","BTI","CLLS","BK4532","BDRX","BK4082","LU0154236417.USD","DAVA","LU0109394709.USD","EDAP","LU0084288595.USD","BK4134","BK4588","BK4139","TEF","BK7104","BK4207","BK4115","BK4162","BK4521","DBVT","PUK","BK4142","IE00BMPRXN33.USD","LU0889565916.HKD","BK7062","EQNR","ASND","BTI.AU","IHG","LU2543165471.USD","LU0648005311.SGD","DAVA.AU","LU1093756325.SGD","LU1093756168.USD","LU0006061336.USD","AKTX","BK4117","AFG","NVO.AU","BK4107","AUTL","LU0320765992.SGD","BK4075","IE00BKVL7J92.USD","BK4547","IE00BZ1G4Q59.USD","NOK"],"gpt_icon":1},{"id":"2590810349","title":"Press Release: Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590810349","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590810349?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:00","pubTimestamp":1765285200,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Dec. 09, 2025  -- Century Therapeutics, Inc. , a biotechnology company developing induced pluripotent stem cell -derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees.Dr. Han Lee most recently served as President and Chief Financial Officer of ImmPACT Bio, Inc., a privately-owned clinical-stage biotechnology company, which was recently acquired by Lyell Immunopharma in 2024. Prior to ImmPACT, he served in the position of Chief Financial Officer at Neogene Therapeutics, Inc. and, before that, at Arcellx, Inc. Earlier in his career, Dr. Lee worked in corporate development and ventures at AstraZeneca plc. He holds a Ph.D. in genetics and an M.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","TM","BK4539","MUR","BK4139","BK4604","AUTL","BK4505","BK4099","BK4555","03160","IPSC","BK4213"],"gpt_icon":0},{"id":"2590358352","title":"European Equities Traded in the US as ADRs Little Changed in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590358352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590358352?lang=en_us&edition=fundamental","pubTime":"2025-12-09 00:01","pubTimestamp":1765209714,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were little changed late Monday morning, easing less than 0.1% to 1,630.2 on the S&P Europe Select ADR Index.From continental Europe,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DEO","AMRN","BK4585","LU0300736062.USD","SNY","EVAX","BK4568","MTLS","BK7511","BK4588","BK4139","AKTX","LU1093756168.USD","IE00BZ1G4Q59.USD","TRIB","LU0124676726.USD","BK4082","BK4169","SLN","BK4532","BNTX","LU0689626769.HKD","LU1093756325.SGD","BK4599","DGE.UK","BK4168","BK4551","BDRX","IE00BFXG1179.USD","LU0154236417.USD","LU0300736492.USD","IE00BKVL7J92.USD","BK4548","UL","BK4559","BK4007","BK4535","BK4023","ULVR.UK","BK7104","BK7507","BK4183","AUTL","EDAP","BK4592","UN","DBVT","BHP","BK7095","BK4546"],"gpt_icon":1},{"id":"2589355990","title":"Autolus Therapeutics Reports High Remission Rates in Pediatric B-ALL with Obe-cel in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355990","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355990?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200913,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics plc announced the presentation of preliminary data from the Phase 1 CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia , as well as additional analyses from the registrational FELIX study in adult r/r B-ALL, at the American Society of Hematology  Annual Meeting. The CATULUS trial data showed a 95.5% overall response rate in pediatric patients, including those with high-risk relapse and primary CNS relapse, with low rates of high-grade cytokine release syndrome  and immune effector cell-associated neurotoxicity syndrome . The FELIX study highlighted product cell phenotype and CAR T-cell persistence at three months as potential predictors of long-term remission. Real-world data from the US commercial launch of obe-cel, collected by the ROCCA consortium, demonstrated high response rates and low levels of high-grade CRS and ICANS, consistent with clinical trial findings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9VqZrC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","BK4588","SG9999014005.SGD","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","AUTL","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2588772473","title":"Autolus Therapeutics Appoints Ryan Richardson to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772473","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772473?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590453,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics plc has appointed Ryan Richardson to its Board of Directors. Richardson brings over 20 years of experience in strategy and corporate development, having previously served as Chief Strategy Officer at BioNTech and held roles at J.P. Morgan and in life sciences consulting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL2gn2Zc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","BK4139","AUTL","BK4585","BK4551","LU2210149790.SGD","NDAQ","BNTX","LU2095319765.USD","BK4548","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","BK4568","LU0314104364.USD","BK4535"],"gpt_icon":0},{"id":"2586266977","title":"European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586266977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586266977?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:03","pubTimestamp":1764172980,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were surging higher late Wednesday morning, rising 1.25% to 1,614.11 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical companies Novo Nordisk  and Ascendis Pharma , which rose 3.5% and 1.8%, respectively. They were followed by biopharmaceutical company DBV Technologies  and lender Banco Santander , which were up 1.7% and 1.6%, respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and brewing company Anheuser-Busch InBev , which fell 4.6% and 1%, respectively. They were followed by biotech firm Evaxion  and pharmaceutical company Sanofi , which were off 0.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and NuCana , which increased 5.5% and 3.7%, respectively. They were followed by lenders Barclays  and Lloyds Banking Group , which advanced 3.2% each.The decliners from the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","BK4599","DGE.UK","LU1093756168.USD","LU0109394709.USD","NCNA","BK4158","IE00BZ1G4Q59.USD","LU0320765992.SGD","BK7104","IE00BFXG1179.USD","BK7119","BUD","SNY","BK4532","DBVT","SAN","NVO","LU0889565916.HKD","NVO.AU","AUTL","BK4007","BK4521","SAN.AU","BCYC","BK4505","IE00BKVL7J92.USD","CLLS","BCS","LYG","DEO","BUD.AU","LU0154236417.USD","MREO","BK4107","EVAX","BK4117","BK4207","BK7142","AFG","ASND","AKTX","LU1093756325.SGD","BK4559","BK4169"],"gpt_icon":1},{"id":"2586558408","title":"Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586558408","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586558408?lang=en_us&edition=fundamental","pubTime":"2025-11-26 01:37","pubTimestamp":1764092220,"startTime":"0","endTime":"0","summary":"U.K.'s NICE issues draft guidance recommending Autolus' Aucatzyl for adult r/r B-ALL, setting up imminent NHS launch and broader patient access.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/25/Scientist-Pipetting-At-A-Biomedical-Labo.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/25/Scientist-Pipetting-At-A-Biomedical-Labo.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/11/49064730/why-is-autolus-therapeutics-stock-trading-higher-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/49064730/why-is-autolus-therapeutics-stock-trading-higher-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","BK4023","LENZ","BK4543","BK4139","AUTL","BK4566","IE00BFMHRM44.USD","BK4539","NICE"],"gpt_icon":0},{"id":"2586475234","title":"Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2586475234","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586475234?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:34","pubTimestamp":1764077683,"startTime":"0","endTime":"0","summary":"Nov 25 (Reuters) - Autolus Therapeutics PLC <6A3Ay.F>::*NICE RECOMMENDS AUCATZYL (OBECABTAGENE AUTOLEUCEL) AS A TREATMENT OPTION FOR ADULT PATIENTS (≥26 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECU","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nRSD69PyGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUTL","BK4139"],"gpt_icon":0},{"id":"2586454429","title":"Autolus Says UK Health Body Recommended Aucatzyl as Treatment Option for Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2586454429","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586454429?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:13","pubTimestamp":1764065602,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics  said Tuesday that the National Institute for Health and Care Excellence has recommended leukemia drug Aucatzyl for use in the National Health Service in England and Wales to treat adult patients.The company said it plans to launch the drug in England and Wales \"imminently.\"Autolus also plans to pursue patient access to the drug through the Scottish Medical Consortium, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AUTL"],"gpt_icon":0},{"id":"2586421889","title":"Autolus Therapeutics announces NICE draft guidance recommending Aucatzyl","url":"https://stock-news.laohu8.com/highlight/detail?id=2586421889","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586421889?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:10","pubTimestamp":1764065421,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) announced that the National Institute for Health and Care Excellence has published draft guidance recommending Aucatzyl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-announces-nice-draft-guidance-recommending-aucatzyl-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-announces-nice-draft-guidance-recommending-aucatzyl-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","NICE","IE00BFMHRM44.USD","BK4007","BK4566","BK4023","LENZ","AUTL","BK4543","BK4139"],"gpt_icon":0},{"id":"2586423152","title":"NICE Recommends Autolus Therapeutics' AUCATZYL for NHS Use in Adult r/r B-ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423152","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586423152?lang=en_us&edition=fundamental","pubTime":"2025-11-25 17:00","pubTimestamp":1764061231,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics plc has announced that the National Institute for Health and Care Excellence  has published draft guidance recommending AUCATZYL  for use in the National Health Service  in England and Wales as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia . AUCATZYL will be available through routine commissioning by the NHS, and Autolus intends to launch the therapy in England and Wales imminently. The company also plans to seek patient access to AUCATZYL in Scotland through the Scottish Medical Consortium.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire  on Nov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL8VHRpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUTL","LU0314104364.USD","LU2210150020.SGD","BK4588","BK4585","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","BK4112"],"gpt_icon":0},{"id":"2585890142","title":"European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down 3% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2585890142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585890142?lang=en_us&edition=fundamental","pubTime":"2025-11-22 00:01","pubTimestamp":1763740869,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were tracking higher Friday morning, rising 0.65% to 1,561.36 on the S&P Europe Select ADR Index, which is down close to 3% for  the wee","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UN","DGE.UK","BK4117","BK4204","MTLS","CLLS","BK4592","BK4023","BK4559","BK7062","BK4139","BK4111","BUD","LU0006061336.USD","LU0124676726.USD","BTI","PSO","BK4158","BK4588","AFG","BK4141","SLN","BK4142","BK4183","BCYC","BK4107","BK4169","ULVR.UK","SQNS","BK4115","BK4075","IHG","BK4546","EVAX","UL","BK7119","BK4585","OPRA","BUD.AU","NCNA","LU0689626769.HKD","BTI.AU","LU2543165471.USD","TEF","AUTL","DEO"],"gpt_icon":0},{"id":"2583205592","title":"European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2583205592","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583205592?lang=en_us&edition=fundamental","pubTime":"2025-11-14 00:19","pubTimestamp":1763050780,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly higher late Thursday morning, rising 0.11% to 1,641.58 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications operator Telefonica  and oil and gas company TotalEnergies , which rose 3.9% and 2.1%, respectively. They were followed by biopharmaceutical company Grifols  and semiconductor company Sequans Communications , which gained 1.9% and 1.3% respectively.The decliners from continental Europe were led by biotech companies BioNTech  and Evaxion , which declined 6.1% and 5% respectively. They were followed by accommodations booking company trivago  and internet browser company Opera , which were down 2.8% and 2.5% respectively.From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics  and biopharmaceutical company Amarin , which advanced 2.4% and 1.3% respectively. They were followed by pharmaceutical company AstraZeneca  and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4009","EVAX","SQNS","BK4201","LU1829250122.USD","BK4023","LU2237443895.HKD","LU2237443382.USD","PSO","AZN","BK4141","BK4505","BK4107","LU0109394709.USD","BK4535","MREO","TRVG","BK4588","TTE","BK4561","LU0889565916.HKD","BNTX","LU2129689605.HKD","LU2417539215.USD","LU2236285917.USD","LU0320765992.SGD","AMRN","AUTL","BK4548","LU2237443465.HKD","LU2129689431.USD","AFG","BK4585","GRFS","BK4115","WPP.AU","BK4139","WPP","BK4111","SLN","LU2237443549.SGD","LU2237443622.USD","BK4568","LU2129689514.USD","LU2456880835.USD","TEF","BDRX","BK4077","OPRA","BK4117"],"gpt_icon":0},{"id":"2583859217","title":"Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Autolus Therapeutics (AUTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583859217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583859217?lang=en_us&edition=fundamental","pubTime":"2025-11-14 00:11","pubTimestamp":1763050292,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PDS Biotechnology (PDSB – Research Report) and Autol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pds-biotechnology-pdsb-and-autolus-therapeutics-autl-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pds-biotechnology-pdsb-and-autolus-therapeutics-autl-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4092","BK4139","BK4581","XBI","HCSG","PDS","AUTL","LU0128526141.USD","BK4137","BK4585","BK4588","XLV","LU0029874061.USD","LABU","PDSB"],"gpt_icon":0},{"id":"2583030913","title":"European Equities Traded in the US as American Depositary Receipts Rise Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2583030913","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583030913?lang=en_us&edition=fundamental","pubTime":"2025-11-13 00:12","pubTimestamp":1762963943,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Wednesday morning, up 0.5% to 1,640.07 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies  and pharmaceutical giant Novo Nordisk , which climbed 5% and 2%, respectively.They were followed by bank Santander , which rose 2.3%.The decliners from continental Europe were led by cybersecurity company Wisekey  and solar energy firm Turbo Energy , which fell 4.9% and 3.2%, respectively.They were followed by energy company Equinor , which was down 2.1%.From the UK and Ireland, the gainers were led by clinical-stage pharmaceutical company Centessa Pharmaceuticals  and Argo Blockchain , which gained 12% and 5.6%, respectively.The decliners from the UK and Ireland were led by early commercial-stage biopharmaceutical company Autolus Therapeutics , which dropped nearly 10%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAN","BK4139","CNTA","BK4539","BK4588","EQNR","AFG","BK4117","BK4096","DBVT","BK4207","SAN.AU","BK4023","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4532","BK4141","ARBK","BK4535","LU1093756168.USD","BK7104","NVO.AU","NVO","BK4599","BK4600","BK4565","BK7142","IE00BKVL7J92.USD","BK4107","BK4007","WKEY","BK4201","AUTL","TURB","BK4595","BK4585","LU1093756325.SGD","BK4521"],"gpt_icon":1},{"id":"2582374925","title":"Autolus Therapeutics Appoints New Principal Accounting Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374925?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:32","pubTimestamp":1762954355,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics ( ($AUTL) ) has provided an announcement. On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/autolus-therapeutics-appoints-new-principal-accounting-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/autolus-therapeutics-appoints-new-principal-accounting-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4162","BK4539","BK4585","BK4139","BK4588","LU1989772840.SGD","BK4566","BK4534","PFG","LU1989772923.USD","AUTL","BK4007","LENZ"],"gpt_icon":0},{"id":"2582189373","title":"Autolus Therapeutics reports Q3 AUCATZYL net product revenue of $21.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582189373","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582189373?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948825,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics plc reported net product revenue of $21.1 million and deferred revenue of $7.6 million for the third quarter ended September 30, 2025. The company recorded a net loss per ordinary share of $0.30 for the quarter, compared to $0.31 for the same period in 2024. Cash, cash equivalents, and marketable securities totaled $367.4 million at September 30, 2025, down from $588.0 million at December 31, 2024, primarily due to net cash used in operating activities and a delayed R&D tax credit receipt of approximately $20.1 million. During the period, Autolus achieved 60 authorized treatment centers for AUCATZYL, ahead of target, and continued clinical data generation to support market growth and expansion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbc4BjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210150020.SGD","AUTL","BK4112","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANNX","RSKD","ABOS","AFYA","ARDT","CPRT","ALUR","ABSI","ASND","AEBI","AUTL","GUTS","TWFG","AMAT","AVBP","BLDP","AFCG","ATAT","IMRX","ALH","CRMD","CINT","IBTA","ALC","AEMD","CSCO","ABEO","ARCO","CELC","BABA","ALVO","CREX","AKRO","AIRG","BEEM","PYPD","CABA","ARX","CURI","CLBT","ATXS","CCAP","MGX","ALMS","CRMT","ACXP","CAAP","LUNG","AYTU"],"gpt_icon":1},{"id":"2582803070","title":"European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2582803070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582803070?lang=en_us&edition=fundamental","pubTime":"2025-11-11 00:05","pubTimestamp":1762790700,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.77% to 1,603.65 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies Cellectis  and Genfit , which climbed 12.2% and 7.2% respectively. They were followed by 3D printer company Materialise  and lender Banco Bilbao Vizcaya Argentaria , which advanced 4.8% and 2.4% respectively.The decliners from continental Europe were led by petroleum refiner Equinor  and telecommunications operator Telefonica , which fell 2.2% and 1.4% respectively. They were followed by consumer goods giant Unilever  and telecommunications company Ericsson , which were down 1% and 0.8% respectively.From the UK and Ireland, the gainers were led by alcoholic beverage company Diageo  and biotech firm Autolus Therapeutics , which rose 4.9% and 2.2% respectively. They were followed by pharmaceutical company AstraZeneca  and biopharmaceutical comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ERIC","AMRN","AKTX","BK4591","SLN","UN","BK4201","LU0084288595.USD","BK4007","LU0109394709.USD","LU2236285917.USD","LU2456880835.USD","UL","BK4559","BK4554","BK4207","BK4183","BBVA","BDRX","AFG","EQNR","BK4107","DAVA","GNFT","BK4117","BK4169","LU0689626769.HKD","BK4023","BK4588","LU0124676726.USD","LU0648005311.SGD","BK4515","LU0320765992.SGD","DGE.UK","DEO","TEF","BK4020","BK4592","BK4546","CLLS","AUTL","DAVA.AU","ULVR.UK","LU0889565916.HKD","LU2462157665.USD","BK4568","AZN","BK4134","MTLS","LU1829250122.USD"],"gpt_icon":0},{"id":"2580421982","title":"Needham Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580421982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580421982?lang=en_us&edition=fundamental","pubTime":"2025-11-04 03:37","pubTimestamp":1762198654,"startTime":"0","endTime":"0","summary":"In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics, with a price target of $10.00. The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-autolus-therapeutics-autl-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-autolus-therapeutics-autl-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUTL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.autolus.com","stockEarnings":[{"period":"1week","weight":0.0387},{"period":"1month","weight":0.1838},{"period":"3month","weight":0.1667},{"period":"6month","weight":-0.2406},{"period":"1year","weight":-0.4015},{"period":"ytd","weight":-0.3149}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.12202},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.090867},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.029231},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.051627},{"month":5,"riseRate":0.714286,"avgChangeRate":0.176061},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.000885},{"month":7,"riseRate":0.375,"avgChangeRate":0.025277},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002702},{"month":9,"riseRate":0.375,"avgChangeRate":-0.079474},{"month":10,"riseRate":0.25,"avgChangeRate":0.011874},{"month":11,"riseRate":0.5,"avgChangeRate":0.135484},{"month":12,"riseRate":0.25,"avgChangeRate":-0.068118}],"exchange":"NASDAQ","name":"Autolus Therapeutics PLC","nameEN":"Autolus Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Autolus Therapeutics PLC(AUTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Autolus Therapeutics PLC(AUTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Autolus Therapeutics PLC,AUTL,Autolus Therapeutics PLC股票,Autolus Therapeutics PLC股票老虎,Autolus Therapeutics PLC股票老虎国际,Autolus Therapeutics PLC行情,Autolus Therapeutics PLC股票行情,Autolus Therapeutics PLC股价,Autolus Therapeutics PLC股市,Autolus Therapeutics PLC股票价格,Autolus Therapeutics PLC股票交易,Autolus Therapeutics PLC股票购买,Autolus Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Autolus Therapeutics PLC(AUTL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Autolus Therapeutics PLC(AUTL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction